TY - JOUR
T1 - An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis
AU - Berry, Matthew P.R.
AU - Graham, Christine M.
AU - McNab, Finlay W.
AU - Xu, Zhaohui
AU - Bloch, Susannah A.A.
AU - Oni, Tolu
AU - Wilkinson, Katalin A.
AU - Banchereau, Romain
AU - Skinner, Jason
AU - Wilkinson, Robert J.
AU - Quinn, Charles
AU - Blankenship, Derek
AU - Dhawan, Ranju
AU - Cush, John J.
AU - Mejias, Asuncion
AU - Ramilo, Octavio
AU - Kon, Onn M.
AU - Pascual, Virginia
AU - Banchereau, Jacques
AU - Chaussabel, Damien
AU - O'Garra, Anne
N1 - Funding Information:
Acknowledgements We thank the patients and volunteer participants. We thank D. Kioussis (MRC National Institute for Medical Research (NIMR)) and D. Young (NIMR) for discussion and input. We thank N. Baldwin (Baylor Institute for Immunology Research (BIIR)) for advice and support on bioinformatics analysis, Q.-A. Nguyen (BIIR) and colleagues for providing technical assistance with microarray processing, and S. Caidan (NIMR), J. Wills (NIMR) and S. Phillips (BIIR) for help and advice with sample storage and transport. We thank the TB service at Imperial College Healthcare NHS Trust, B.M. Haselden and the TB service at Hillingdon Hospital, Uxbridge, UK. We also thank H. Giedon and R. Seldon for help in laboratory analyses, and Y. Hlombe for recruitment of patients and follow-up in South Africa. A. Rae (NIMR), T. Dipucchio (BIIR) and K. Palucka (BIIR) provided advice on flow cytometry. We thank G. Hayward for help depositing the microarray data. We thank J. Brock (NIMR) for help with graphics. M.P.R.B. was supported by an MRC career development fellowship and a grant from the Dana Foundation Program in Human Immunology. The research was funded by the Medical Research Council, UK, MRC Grant U117565642 and The Dana Foundation Program in Human Immunology. A.O’G., C.M.G. and F.W.McN. are funded by the Medical Research Council, UK. V.P. is supported by National Institutes of Health (NIH) R01 AR050770-01, NIH P50 ARO54083 and NIH 1 U19 AI082715-01. The work of J.B., D.C. and V.P. is supported by the Baylor Health Care System Foundation and the NIH (U19 AIO57234-02, U01 AI082110, P01 CA084512).
PY - 2010/8/19
Y1 - 2010/8/19
N2 - Tuberculosis (TB), caused by infection with Mycobacterium tuberculosis, is a major cause of morbidity and mortality worldwide. Efforts to control it are hampered by difficulties with diagnosis, prevention and treatment. Most people infected with M. tuberculosis remain asymptomatic, termed latent TB, with a 10% lifetime risk of developing active TB disease. Current tests, however, cannot identify which individuals will develop disease. The immune response to M. tuberculosis is complex and incompletely characterized, hindering development of new diagnostics, therapies and vaccines. Here we identify a whole-blood 393 transcript signature for active TB in intermediate and high-burden settings, correlating with radiological extent of disease and reverting to that of healthy controls after treatment. A subset of patients with latent TB had signatures similar to those in patients with active TB. We also identify a specific 86-transcript signature that discriminates active TB from other inflammatory and infectious diseases. Modular and pathway analysis revealed that the TB signature was dominated by a neutrophil-driven interferon (IFN)-inducible gene profile, consisting of both IFN-γ and type I IFN-αβ signalling. Comparison with transcriptional signatures in purified cells and flow cytometric analysis suggest that this TB signature reflects changes in cellular composition and altered gene expression. Although an IFN-inducible signature was also observed in whole blood of patients with systemic lupus erythematosus (SLE), their complete modular signature differed from TB, with increased abundance of plasma cell transcripts. Our studies demonstrate a hitherto underappreciated role of type I IFN-αβ signalling in the pathogenesis of TB, which has implications for vaccine and therapeutic development. Our study also provides a broad range of transcriptional biomarkers with potential as diagnostic and prognostic tools to combat the TB epidemic.
AB - Tuberculosis (TB), caused by infection with Mycobacterium tuberculosis, is a major cause of morbidity and mortality worldwide. Efforts to control it are hampered by difficulties with diagnosis, prevention and treatment. Most people infected with M. tuberculosis remain asymptomatic, termed latent TB, with a 10% lifetime risk of developing active TB disease. Current tests, however, cannot identify which individuals will develop disease. The immune response to M. tuberculosis is complex and incompletely characterized, hindering development of new diagnostics, therapies and vaccines. Here we identify a whole-blood 393 transcript signature for active TB in intermediate and high-burden settings, correlating with radiological extent of disease and reverting to that of healthy controls after treatment. A subset of patients with latent TB had signatures similar to those in patients with active TB. We also identify a specific 86-transcript signature that discriminates active TB from other inflammatory and infectious diseases. Modular and pathway analysis revealed that the TB signature was dominated by a neutrophil-driven interferon (IFN)-inducible gene profile, consisting of both IFN-γ and type I IFN-αβ signalling. Comparison with transcriptional signatures in purified cells and flow cytometric analysis suggest that this TB signature reflects changes in cellular composition and altered gene expression. Although an IFN-inducible signature was also observed in whole blood of patients with systemic lupus erythematosus (SLE), their complete modular signature differed from TB, with increased abundance of plasma cell transcripts. Our studies demonstrate a hitherto underappreciated role of type I IFN-αβ signalling in the pathogenesis of TB, which has implications for vaccine and therapeutic development. Our study also provides a broad range of transcriptional biomarkers with potential as diagnostic and prognostic tools to combat the TB epidemic.
UR - http://www.scopus.com/inward/record.url?scp=77955894773&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955894773&partnerID=8YFLogxK
U2 - 10.1038/nature09247
DO - 10.1038/nature09247
M3 - Article
C2 - 20725040
AN - SCOPUS:77955894773
SN - 0028-0836
VL - 466
SP - 973
EP - 977
JO - Nature
JF - Nature
IS - 7309
ER -